These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32946721)

  • 1. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017.
    Shimbashi R; Suzuki M; Chang B; Watanabe H; Tanabe Y; Kuronuma K; Oshima K; Maruyama T; Takeda H; Kasahara K; Fujita J; Nishi J; Kubota T; Tanaka-Taya K; Matsui T; Sunagawa T; Oishi K;
    Emerg Infect Dis; 2020 Oct; 26(10):2378-2386. PubMed ID: 32946721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019.
    Tamura K; Chang B; Shimbashi R; Watanabe H; Tanabe Y; Kuronuma K; Oshima K; Maruyama T; Fujita J; Abe S; Kasahara K; Nishi J; Kubota T; Kinjo Y; Fujikura H; Fukusumi M; Shimada T; Sunagawa T; Suzuki M; Yamamoto Y; Oishi K;
    Vaccine; 2022 May; 40(24):3338-3344. PubMed ID: 35489986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark.
    Nielsen KF; Nielsen LB; Dalby T; Lomholt FK; Slotved HC; Fuursted K; Harboe ZB; Jørgensen CS; Valentiner-Branth P
    Emerg Infect Dis; 2024 Jun; 30(6):1164-1172. PubMed ID: 38781925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the changing pneumococcal national immunisation program among older Australians.
    Menzies R; Stein AN; Booy R; Van Buynder PG; Litt J; Cripps AW
    Vaccine; 2021 Jan; 39(4):720-728. PubMed ID: 33384189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States.
    Ahmed SS; Pondo T; Xing W; McGee L; Farley M; Schaffner W; Thomas A; Reingold A; Harrison LH; Lynfield R; Rowlands J; Bennett N; Petit S; Barnes M; Smelser C; Beall B; Whitney CG; Pilishvili T
    Clin Infect Dis; 2020 Jun; 70(12):2484-2492. PubMed ID: 31402387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.
    Nzenze SA; Madhi SA; Shiri T; Klugman KP; de Gouveia L; Moore DP; Karstaedt AS; Tempia S; Nunes MC; von Gottberg A
    Am J Epidemiol; 2017 Aug; 186(4):435-444. PubMed ID: 28482004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
    Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
    Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
    Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
    Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013.
    Ubukata K; Chiba N; Hanada S; Morozumi M; Wajima T; Shouji M; Iwata S;
    Emerg Infect Dis; 2015 Nov; 21(11):1956-65. PubMed ID: 26485679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
    Su WJ; Chuang PH; Chang LY; Lo HY; Chiang CS; Wang ET; Yang CH
    BMC Infect Dis; 2021 Jan; 21(1):45. PubMed ID: 33423657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
    Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
    Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
    Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution.
    Fukusumi M; Chang B; Tanabe Y; Oshima K; Maruyama T; Watanabe H; Kuronuma K; Kasahara K; Takeda H; Nishi J; Fujita J; Kubota T; Sunagawa T; Matsui T; Oishi K;
    BMC Infect Dis; 2017 Jan; 17(1):2. PubMed ID: 28049447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
    Dinleyici EC; Yargic ZA
    Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.